Stock ALTHX THERANEXUS
Add to a list
To use this feature you must be a member
Log inSign up

All News Theranexus

Equities

ALTHX

FR0013286259

Market Closed - Euronext Paris
Other stock markets
 11:35:24 2024-04-19 am EDT 		5-day change 1st Jan Change
1.05 EUR -0.47% Intraday chart for Theranexus -7.89% -6.25%
12:10pm Theranexus: share price rises following promising trial results CF
Mar. 11 Theranexus: CEO takes over as Chairman of the Board CF

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Theranexus: share price rises following promising trial results
CF
Theranexus : Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1
AT
Theranexus: CEO takes over as Chairman of the Board
CF
Theranexus : THERANEXUS ANNOUNCES APPOINTMENT OF MATHIEU CHARVÉRIAT AS BOARD OF DIRECTORS CHAIRMAN
AT
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS
AT
Certain Ordinary Shares of Theranexus Société Anonyme are subject to a Lock-Up Agreement Ending on 11-JAN-2024.
CI
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023
AT
Theranexus : Theranexus : Highly Promising 12-month results in the Phase I/II trial of Batten-1
AT
Theranexus : THERANEXUS ANNOUNCES FIRST HALF 2023 FINANCIAL RESULTS
AT
Theranexus Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Theranexus : Theranexus raises around 3.1 million euros in fundraising
AT
Theranexus Société Anonyme announced that it has received €2.470412 million in funding
CI
Theranexus : Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in Batten disease (CLN3)
AT
Global markets live: Lucid, Under Armour, Coty, PayPal, Western Digital...
Our Logo
Theranexus : Theranexus and BBDF win FDA approval on efficacy endpoints for the Phase III trial to evaluate Batten-1 in CLN3 Batten disease
AT
Theranexus and BBDF Win FDA Approval on Efficacy Endpoints for the Phase III Trial to Evaluate Batten-1 in CLN3 Batten Disease
CI
Theranexus Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Theranexus : THERANEXUS PUBLISHES ITS 2022 FULL-YEAR RESULTS AND PRESENTS AN UPDATE ON ITS PROGRAMS
AT
Theranexus : THERANEXUS, BBDF AND CARDIFF UNIVERSITY PRESENT THEIR NOVEL RESEARCH ON BATTEN-1 AND BATTEN DISEASE AT WORLDSYMPOSIUM 2023
AT
Theranexus : AISTROSIGHT: NEW JOINT PROJECT TEAM BETWEEN THERANEXUS, INRIA, CLAUDE BERNARD UNIVERSITY LYON 1 AND HOSPICES CIVILS DE LYON TARGETING RARE NEUROLOGICAL DISEASES
AT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALTHX Stock
  4. News Theranexus